PDCD1 and familial pancreatic carcinoma: Empirical data has evidenced that the strategic inhibition of targets such as Pin1, MEK, STAT3, ARG1 can significantly elevate the response rates of pancreatic neoplasms to anti-PD1 therapy (55, 56), enable more pancreatic cancer patients to benefit from immunotherapy.